Sobi launch Doptelet® (avatrombopag) in Europe

The UK will be the first country for launch for this thrombopoietin receptor agonist that is approved for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.

SPS commentary:

NICE has approved avatrombopag, within its marketing authorisation, as an option for treating severe thrombocytopenia (i.e. platelet count <50,000 per microlitre of blood).

Source:

Biospace Inc.

Resource links:

NICE Technology appraisal guidance [TA626]